Heart beat line end of life
Our Work

Latham & Watkins Advises Affera in Its Sale to Medtronic

January 10, 2022
A Boston-based team advises the medical technology company in the transaction.

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has announced that it has entered into a definitive agreement to acquire Affera, Inc., a Boston area-based, privately held medical technology company. Affera designs and manufactures cardiac mapping and navigation systems and catheter-based cardiac ablation technologies, including a differentiated, focal pulsed field ablation solution, for the treatment of patients with cardiac arrhythmias (irregular heartbeats) such as atrial fibrillation (AF). Medtronic, through its minority investment portfolio, has been a strategic investor in Affera and currently holds a 3% ownership stake in the company.

Latham & Watkins LLP represents Affera, Inc. in the transaction with a corporate deal team led by Boston partner Hans Brigham, with Boston associates Stefanie Vincent, Michael Casagrande, and Matthew Farina. Advice was also provided on benefits and compensation matters by New York partner Austin Ozawa, with New York associate Anne Bracaglia; on tax matters by Bay Area partner Grace Lee, with Bay Area associate Jake Meninga; on intellectual property matters by Boston partner Sarah Gagan, with Boston associate Seth Appiah-Opoku; on antitrust matters by Washington, D.C. partner Mandy Reeves, London partner Jonathan Parker and Washington, D.C. counsel Patrick English, with London associate Greg Bonné; on FDA matters by Washington, D.C. associate Chad Jennings; on regulatory matters by Washington, D.C. partner Elizabeth Richards and Paris partner Eveline Van Keymeulen; on healthcare regulatory matters by Bay Area counsel Betty Pang; on data privacy matters by Bay Area counsel Heather Deixler; and on other corporate matters by Boston associates Luke Schafer and Tyler Mills.